Teva Pharmaceutical Industries (TEVA) Common Equity (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Common Equity for 18 consecutive years, with $7.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 13.51% year-over-year to $7.8 billion; the trailing twelve-month figure through Jun 2026 stood at $7.8 billion (up 13.51% YoY), and the FY2025 full-year result was $7.9 billion, up 47.1% from the prior year.
• Common Equity fell to $7.8 billion in Q2 2026 per TEVA's latest filing, from $8.2 billion in the prior quarter.
• Across five years, Common Equity topped out at $10.3 billion in Q1 2022 and bottomed at $5.4 billion in Q4 2024.
• Historically, Common Equity has averaged $7.8 billion across 5 years, with a median of $7.7 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 33.79% in 2024, then soared 47.1% in 2025.
• Over 5 years, Common Equity stood at $8.6 billion in 2022, then dropped by 5.49% to $8.1 billion in 2023, then tumbled by 33.79% to $5.4 billion in 2024, then surged by 47.1% to $7.9 billion in 2025, then dropped by 1.98% to $7.8 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $7.8 billion, $8.2 billion, and $7.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.